Form 4: KORU Medical CFO Granted 75,000 Restricted Stock Units

KORU Medical Systems' Chief Financial Officer, Thomas Edward Adams, was granted 75,000 restricted stock units under the company's 2024 Omnibus Equity Incentive Plan.

Summary

• Thomas Edward Adams, Chief Financial Officer of KORU Medical Systems, Inc. (KRMD), was granted 75,000 Restricted Stock Units (RSUs).
• The grant was made on January 2, 2026, under the Company's 2024 Omnibus Equity Incentive Plan.
• Each RSU represents a contingent right to receive one share of KORU Medical Systems common stock upon vesting.
• The RSUs will vest in four equal annual installments, with the first quarter vesting on January 2, 2027, and subsequent quarters vesting on each first, second, and third anniversary thereafter.
• Vesting may also accelerate upon an earlier change in control of the Company.
• Following this transaction, Thomas Adams beneficially owns 75,000 derivative securities (RSUs).

Sentiment

Score: 6

Explanation: The grant of equity to a key executive is generally viewed as a positive for aligning interests and retention, but it's a routine compensation event rather than a significant operational or financial announcement. The potential for future dilution is a minor consideration.

Positives

• The grant of 75,000 Restricted Stock Units to the Chief Financial Officer aligns management's interests with long-term shareholder value through equity ownership.
• The vesting schedule, extending over four years, incentivizes long-term retention and performance from a key executive.

Negatives

• The future issuance of 75,000 shares upon vesting of the Restricted Stock Units represents potential dilution for existing shareholders, though this is a standard component of equity compensation plans.

Future Outlook

The multi-year vesting schedule for the Restricted Stock Units indicates a strategic approach to executive retention and incentivizes the Chief Financial Officer to contribute to the company's long-term performance and value creation.

Industry Context

The grant of Restricted Stock Units to a Chief Financial Officer is a common practice in the medical systems industry and broader corporate landscape, serving as a key component of executive compensation packages designed to attract, retain, and motivate senior leadership by aligning their financial interests with those of shareholders.

Comparison to Industry Standards

• Equity compensation, particularly through Restricted Stock Units (RSUs), is a standard practice for executive remuneration across various industries, including medical systems.
• The four-year vesting schedule is typical for such grants, comparable to practices at companies like Medtronic (MDT) or Stryker (SYK), which often use multi-year vesting to ensure long-term executive commitment.
• The grant size of 75,000 units for a CFO at a company like KORU Medical Systems (market cap around $100-200M) appears within a reasonable range for incentivizing a key executive, though specific comparisons would require detailed compensation peer group analysis.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential long-term alignment of management interests with shareholder value; minor potential future dilution from share issuance upon vesting.
• Employees: May signal stability in executive leadership and the company's commitment to its compensation plans.

Next Steps

• Continued service of Thomas Edward Adams as Chief Financial Officer.
• Vesting of the Restricted Stock Units according to the established schedule, commencing January 2, 2027.
• Potential issuance of common stock upon vesting of the RSUs.

Key Dates

Keywords

KORU Medical Systems, KRMD, Restricted Stock Units, RSU Grant, Equity Incentive Plan, Insider Transaction, Form 4, Thomas Adams, Chief Financial Officer, Executive Compensation